No Spironolactone
Phase 1Small molecule
No Spironolactone is one of 23 small molecule programs targeting Atrial Fibrillation. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
376 competitors in Atrial Fibrillation
#DrugCompanyPhaseTrials
1Xylocaine
MMEDRx USA, Inc.
Preclinical
Anticoagulants
SanofiPreclinical
Direct Anticoagulant
BayerPreclinical
SGLT2 Inhibitor
Eli LillyPreclinical
Statin
Bristol-Myers SquibbPreclinical
Warfarin Sodium
Boehringer IngelheimPreclinical
Magnesium SO4
HHospital de Base
Preclinical
Medication
NNYU Langone Health
Preclinical
Anticoagulation
HHospital Álvaro Cunqueiro
Preclinical
No Spironolactone
PPiedmont Healthcare
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for No Spironolactone. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- PPiedmont Healthcare